Lista de obras - Bob W van Oosten - Dominio Público Uruguay

A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.

artículo científico publicado en 1996

Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation

scientific article published on 19 April 2019

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy

artículo científico publicado en 2014

Author response

scientific article published on 01 July 2013

Brain miliary enhancement

artículo científico publicado en 2020

CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS

artículo científico publicado en 2019

Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases

artículo científico

Choosing drug therapy for multiple sclerosis. An update.

artículo científico publicado en 1998

Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases

artículo científico publicado en 2020

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

artículo científico publicado en 2017

Emerging safety issues in alemtuzumab-treated MS patients

artículo científico publicado en 2019

Erratum to: Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases

scientific article published on 01 August 2017

Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature

artículo científico publicado en 2014

High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate

artículo científico publicado en 2019

Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.

artículo científico publicado en 1998

Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS

scientific article published on 01 February 2011

Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis

artículo científico publicado en 1995

Interleukin-2 therapy does not exacerbate multiple sclerosis

scientific article published on 01 August 1997

More on PML in Patients Treated with Dimethyl Fumarate. Author reply

artículo científico publicado en 2016

Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.

artículo científico publicado en 2004

Multiple sclerosis therapy. A practical guide.

artículo científico publicado en 1995

Neuromyelitis optica spectrum disorder mimicking multiple sclerosis.

artículo científico publicado en 2017

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

artículo científico publicado en 2013

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate

artículo científico publicado en 2015

Patients' expectations of autologous hematopoietic stem cell transplantation as a treatment for MS

scientific article published on 24 October 2019

Progressive cognitive disturbances in a 17-year-old boy

artículo científico publicado en 2015

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases

artículo científico publicado en 2017

Response: Brain miliary enhancement

scientific article published on 25 March 2020

Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy

artículo científico publicado en 2019

TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients

artículo científico publicado en 1997

Time is vision in recurrent optic neuritis

artículo científico publicado en 2017

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

artículo científico publicado en 1997

What went wrong? The flawed concept of cerebrospinal venous insufficiency.

artículo científico publicado en 2013

Whipple's disease in mentally retarded patients: report of two cases

scientific article published on 21 June 2007

Lista de obras de Bob W van Oosten

A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis.

Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy

Author response

Brain miliary enhancement

CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS

Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases

Choosing drug therapy for multiple sclerosis. An update.

Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Emerging safety issues in alemtuzumab-treated MS patients

Erratum to: Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases

Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature

High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate

Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.

Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS

Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis

Interleukin-2 therapy does not exacerbate multiple sclerosis

More on PML in Patients Treated with Dimethyl Fumarate. Author reply

Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.

Multiple sclerosis therapy. A practical guide.

Neuromyelitis optica spectrum disorder mimicking multiple sclerosis.

PML in a patient treated with dimethyl fumarate from a compounding pharmacy

PML in a patient without severe lymphocytopenia receiving dimethyl fumarate

Patients' expectations of autologous hematopoietic stem cell transplantation as a treatment for MS

Progressive cognitive disturbances in a 17-year-old boy

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases

Response: Brain miliary enhancement

Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy

TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients

Time is vision in recurrent optic neuritis

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

What went wrong? The flawed concept of cerebrospinal venous insufficiency.

Whipple's disease in mentally retarded patients: report of two cases